Anixa Biosciences (NASDAQ:ANIX – Get Free Report) and Tevogen Bio (NASDAQ:TVGN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
Volatility & Risk
Anixa Biosciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.
Earnings and Valuation
This table compares Anixa Biosciences and Tevogen Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anixa Biosciences | $210,000.00 | 507.06 | -$10.93 million | ($0.31) | -10.10 |
| Tevogen Bio | N/A | N/A | -$26.27 million | ($4.63) | -1.55 |
Anixa Biosciences has higher revenue and earnings than Tevogen Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Anixa Biosciences and Tevogen Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anixa Biosciences | N/A | -71.12% | -62.88% |
| Tevogen Bio | N/A | N/A | -468.32% |
Institutional & Insider Ownership
29.1% of Anixa Biosciences shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 65.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Anixa Biosciences and Tevogen Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anixa Biosciences | 1 | 1 | 3 | 0 | 2.40 |
| Tevogen Bio | 1 | 1 | 0 | 0 | 1.50 |
Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 171.57%. Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,294.70%. Given Tevogen Bio’s higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Anixa Biosciences.
Summary
Anixa Biosciences beats Tevogen Bio on 8 of the 12 factors compared between the two stocks.
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
